|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 359.97 USD | +0.46% |
|
+4.65% | +10.22% |
| Jun. 26 | US FDA greenlights Viridian's thyroid eye disease drug | RE |
| Jun. 26 | US FDA greenlights Viridian's eye disease drug | RE |
| Market Cap | 193B 169B 156B 146B 275B 18,284B 281B 1,881B 726B 9,020B 726B 710B 31,317B | P/E 2026 * |
23.3x | P/E 2027 * | 21.2x |
|---|---|---|---|---|---|
| Enterprise Value | 235B 205B 190B 177B 333B 22,182B 341B 2,282B 881B 10,943B 881B 862B 37,994B | EV / Sales 2026 * |
6.21x | EV / Sales 2027 * | 5.9x |
| Free-Float |
99.78% | Yield 2026 * |
2.81% | Yield 2027 * | 2.97% |
Last Transcript: Amgen Inc.
| 1 day | +0.52% | ||
| 1 week | +4.59% | ||
| Current month | +7.05% | ||
| 1 month | +7.05% | ||
| 3 months | +3.31% | ||
| 6 months | +9.38% | ||
| Current year | +10.16% |
| 1 week | 345.49 |  | 363.11 |
| 1 month | 322.3 | | 363.11 |
| Current year | 318.21 | | 391.29 |
| 1 year | 269.77 | | 391.29 |
| 3 years | 218.44 | | 391.29 |
| 5 years | 198.64 | | 391.29 |
| 10 years | 133.64 | | 391.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 2012-04-30 |
Peter Griffith
DFI | Director of Finance/CFO | 67 | 2019-12-31 |
Esteban Santos
COO | Chief Operating Officer | 59 | 2016-07-24 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 2012-12-31 |
Tyler Jacks
BRD | Director/Board Member | 65 | 2011-12-31 |
Robert Eckert
BRD | Director/Board Member | 71 | 2011-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| May. 18 | Free | Director | 665 | 0.0001% | ||
| May. 18 | Free | Director | 665 | 0.0001% | ||
| May. 18 | Free | Director | 665 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.53% | +4.59% | +29.13% | +63.03% | 193B | |
| +1.47% | +11.27% | +57.31% | +164.01% | 1,077B | |
| +1.24% | +11.12% | +68.25% | +56.61% | 613B | |
| +0.74% | +10.96% | +37.50% | +91.57% | 448B | |
| +1.86% | +4.85% | +28.17% | +22.04% | 332B | |
| -0.14% | +7.58% | +41.28% | +27.25% | 293B | |
| -0.06% | +4.92% | +31.23% | +41.59% | 286B | |
| -0.96% | +4.98% | -28.37% | -40.96% | 215B | |
| -1.45% | +0.91% | +13.65% | +65.77% | 159B | |
| +0.23% | -3.05% | +0.31% | -32.68% | 138B | |
| Average | +0.34% | +7.26% | +27.85% | +45.82% | 375.45B | |
| Weighted average by Cap. | +0.74% | +9.16% | +40.62% | +76.94% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 37.78B 33.08B 30.54B 28.52B 53.68B 3,572B 54.91B 367B 142B 1,762B 142B 139B 6,118B | 38.75B 33.93B 31.32B 29.25B 55.06B 3,663B 56.31B 377B 146B 1,807B 146B 142B 6,275B |
| Net income | 8.26B 7.24B 6.68B 6.24B 11.74B 781B 12.01B 80.39B 31.04B 385B 31.04B 30.36B 1,338B | 9.04B 7.92B 7.31B 6.82B 12.85B 855B 13.14B 87.94B 33.95B 422B 33.95B 33.21B 1,464B |
| Net Debt | 41.23B 36.1B 33.33B 31.12B 58.59B 3,898B 59.92B 401B 155B 1,923B 155B 151B 6,677B | 35.08B 30.72B 28.36B 26.48B 49.85B 3,317B 50.99B 341B 132B 1,636B 132B 129B 5,681B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-29 | $360.84 | +0.70% | 1,140,682 |
| 26-06-26 | $358.33 | +1.56% | 3,610,561 |
| 26-06-25 | $352.82 | +0.40% | 2,341,847 |
| 26-06-24 | $351.43 | +1.27% | 2,391,890 |
| 26-06-23 | $347.01 | +0.66% | 2,304,951 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AMGN Stock
Select your edition
All financial news and data tailored to specific country editions
